Clinical Trial

Immuno-Therapy

Study Description

An Investigational Immuno-therapy Study of Experimental Medication BMS-986179 Given Alone and in Combination With Nivolumab

The purpose of this study is to assess the safety and tumor-shrinking ability of experimental medication BMS-986179 alone and when combined with Nivolumab, in patients with solid cancers that are advanced or have spread.

Location

Locations Selected Location

Methods

No pharmaceutical medication involved No pharmaceutical medication involved
Recruiting patients only Recruiting patients only

Biological - BMS-986179

Specified dose on specified days

Biological - Nivolumab

Specified dose on specified days

Biological - rHuPH20

Specified dose on specified days

Additional Information

Official Study Title

A Phase 1/2a Study of BMS-986179 Administered Alone and in Combination With Nivolumab (BMS-936558) in Subjects With Advanced Solid Tumors

Clinical Trial ID

NCT02754141

ParticipAid ID

mepoQd